Role of preliminary registry data in development of a clinical trial for an innovative device: a small but integral piece of a health policy initiative by Ricci, D.R. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/170343
 
 
 
Please be advised that this information was generated on 2017-12-07 and may be subject to
change.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=zjma20
Download by: [Radboud Universiteit Nijmegen] Date: 12 June 2017, At: 03:31
Journal of Market Access & Health Policy
ISSN: (Print) 2001-6689 (Online) Journal homepage: http://www.tandfonline.com/loi/zjma20
Role of preliminary registry data in development
of a clinical trial for an innovative device: a small
but integral piece of a health policy initiative
Donald R. Ricci, Joost de Vries & Raphael Blanc
To cite this article: Donald R. Ricci, Joost de Vries & Raphael Blanc (2017) Role of preliminary
registry data in development of a clinical trial for an innovative device: a small but integral
piece of a health policy initiative, Journal of Market Access & Health Policy, 5:1, 1283106, DOI:
10.1080/20016689.2017.1283106
To link to this article:  http://dx.doi.org/10.1080/20016689.2017.1283106
© 2017 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 02 Mar 2017.
Submit your article to this journal 
Article views: 74
View related articles 
View Crossmark data
SHORT COMMUNICATION
Role of preliminary registry data in development of a clinical trial for an
innovative device: a small but integral piece of a health policy initiative
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ABSTRACT
Establishing a national health policy at a macro level involves the integration of a series of health
initiatives across a spectrum of activities, including clinical care. Evaluation of the safety and
efficacy of a new medical device ultimately evolves to testing in humans. The pathway to a formal
prospective clinical trial includes a stepwise appreciation of pre-clinical data and detailed analysis
of data obtained from preliminary registries, where information about appropriate patient selec-
tion and use of the device is obtained. Evaluation of procedural and follow-up efficacy and safety
data in a preliminary series of cases, chosen to simulate published data, allows the design and
conduct of clinical trials that are required to verify preliminary observations, closing the loop on
one aspect of modifying health policy decisions.
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Introduction
Establishing a national health policy at a macro level
involves the integration of a series of health initiatives
across a spectrum of activities, including clinical care.
The World Health Organization’s statement is that ‘out-
comes can be improved through increased and more
focused investment in monitoring and evaluating how
national health policies, strategies, and plans are imple-
mented . . . when properly designed, this allows for
learning, continuous improvement of the planning pro-
cess and timely corrective measures. It also contributes
to documenting policy reform processes.’[1] One of
these activities is the conduct of a clinical trial designed
to determine utility of a new drug or device in the
management schema of a disease entity.
Evaluation of the safety and efficacy of a new med-
ical device begins with intensive pre-clinical (‘bench’
and animal) testing but must, at some stage, evolve to
testing in humans who suffer from the disease entity
that the device was designed to treat. This should occur
cautiously and deliberately by highly experienced and
skillful clinicians familiar with the disease entity, the
device, the clinical milieu and the conduct of clinical
trials. The purpose of this brief communication is to
describe the rationale used to initiate a formal prospec-
tive clinical trial of an innovative device, eCLIPs (eVasc
Neurovascular Enterprises ULC, eVasc Medical Systems
Corp, Vancouver, Canada), using data from an ad hoc
registry developed for the purpose. The approach to
training for the use of new medical devices has already
been described.[2]
Study perspective
The eCLIPs Device is a self-expanding nitinol non-cir-
cumferential device with anchor and leaf segments
(Figure 1), the latter bridging the neck and allowing
for coil retention, flow diversion, a platform for
endothelial growth so that the aneurysm closes perma-
nently by thrombosis and cicatrization, and allowing
the device to be incorporated into the vessel wall.
It was designed to embody features that met specific
unmet needs in management of intracranial bifurcation
aneurysms, particularly those with a wide neck, an espe-
cially complex type of anatomy (i.e. the basilar artery or
carotid terminus) that have had a variety of off-label treat-
ment approaches that have not resulted in consistently
good long term outcomes. The features of the eCLIPs
system include: device removable, retractable and reposi-
tionable before detachment; non-shortening on deploy-
ment; absence of device migration; stable platform
during coil delivery; coil retention; flow disruption away
from the aneurysm; platform for endothelial growth; no
compromise of access to side branches and good wall
apposition accruing to its non-circumferential design. Pre-
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clinical clinical assessment of the eCLIPs device in a rabbit
model of bifurcation aneurysms shows adherence to these
features required for definitive and sustained aneurysm
exclusion from the circulation and incorporation of the
device into the vessel wall to produce a physiologic remo-
deling of the aneurysm.[3]
Un-ruptured or stabilized ruptured aneurysms at the
bifurcation of the basilar artery or carotid terminus are a
rare anatomic subset of bifurcation intracranial aneur-
ysms. Currently no standard of care is available to man-
age this type of aneurysm. Current options for the
endovascular treatment of bifurcation aneurysms
include (i) simple coiling (no stent) and balloon remo-
deling; (ii) the use of commercially available stents ‘off-
label’ to create a Y- or T-stent in conjunction with coils;
(iii) coil retaining devices; and (iv) intrasaccular devices.
However, all these techniques have limitations.
Simple coiling of bifurcation aneurysms is associated
with significantly higher aneurysm recurrence rates
compared to sidewall aneurysms: a recurrence rate of
35% at an average follow-up of 30 months,[4] a large
proportion of which was due to coil compaction.[5]
Stent assisted coiling using a variety of stents and
various techniques has not improved on the aneurysm
recurrence rate at between 18% and 37%.[6–10]
Y-stent assisted coiling, first proposed by Chow et al in
2004,[11] is performed in Y-shaped bifurcations by placing
two stents in the parent artery with each stent in one of the
bifurcation branches, creating a new bifurcation point
across the neck of the aneurysm.[11] However, placing
two stents in this manner is a compromise that does not
allow either stent to bridge the aneurysm neck at its mid-
portion because of a necessary triangular gap that exists
(Figure 2); it leaves more metal in the arterial system
permanently to serve as a source for thrombi or emboli,
impedes access to side branches and perforators, and
doubles the cost compared with placing one stent in
optimal position.[12] Small series have confirmed the fea-
sibility of the procedure, but associated with high risk.
Bartolini et al. [13] suggested that Y and X stent-assisted
coiling was associated with a high rate of complications,
10%procedure-related permanentmorbidity, and 1%mor-
tality rate. Outcome data for coil retaining devices are
sparse and indicate in various time periods of follow-up
an important rate of aneurysm recurrence or persistence.
[14–18] Intrasaccular devices are gaining in popularity, but
these also show a significant rate of aneurysm recurrence
or persistence.[14,19–23] The primary reason for the uni-
versal and apparently consistent rate of recurrence at the
site of a bifurcation is speculated to be the unimpeded
water hammer effect, or the jet effect of blood flow, from
the main vessel into the aneurysm,[24,25] resulting in coil
compaction. Coil retaining devices do not mitigate the
water hammer effect. Compaction of intrasaccular devices
is also apparent.[22] The features designed into the eCLIPs
device, particularly the neck bridging and its attendant
attributes, may reduce or obliterate this effect.
Methodology
Initial eCLIPs implants took place in 2013 under Health
Canada’s Special Access Program. This program ‘permits
health care professionals to access custom-made and unli-
censed medical devices for emergency use or when con-
ventional therapies have failed, are unavailable or are
unsuitable to provide a diagnosis, treatment or prevention
for patients under their care.’[26] The intent of these
Figure 1. (a). Illustration of eCLIPs device in 3-D (left), side (middle) and plan (right) views. (b). Illustration of eCLIPs device deployed
with anchor segment in sidebranch and leaf portion bridging the neck, behind which are coils delivered by catheter penetrating ribs
of leaf portion.
Figure 2. Illustration of dual Y-stenting in bifurcation aneurysm
glass model, showing triangular gap between stents and neck
of aneurysm.
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implants was to obtain ‘first in human’ experience in a
patient population that had no other therapeutic option
and, at the discretion of their treating physicians, had a
reasonable chance of clinical benefit from the eCLIPs
device. Experience using the eCLIPs device also came
from European implants after granting of CE Mark status
in 2014. Each case, and its follow-up, was reviewed by a
multidisciplinary team. This combined early experience,
comprising a registry covering 13 international centers,
allowed the operators to learn the nuances of device
implantation – the ‘learning curve’[2] and identify anatomic
variants that are particularly suited, and those that are not,
to eCLIPs usage. Critical to this process is collection of acute
procedural and follow-up safety and outcome data in all
patients. These earliest results have been reported [27] and
contain the entirety of the experience in the first 33
patients, including patients who would not qualify under
CE Mark granted Indications for Use (‘treatment of intra-
cranial aneurysms arising from bifurcation branch artery
diameters in the range of 2.0 mm–3.25 mm’) or FDA
Humanitarian Use Designation criteria (‘intracranial saccu-
lar aneurysm with a diameter of >5 mm arising at the
internal carotid artery bifurcation or the basilar artery bifur-
cation, with a bifurcation branch artery diameter in the
range of 2.0 mm–3.25 mm’). In order to obtain data that
would allow at least an approximate comparison with
published outcomes, it is important to analyze results in
patients who meet certain inclusion and exclusion criteria.
These results may then define a cohort that may be the
subject of a formal prospective clinical trial.
Results
Efficacy
Figure 3 shows a flow chart of the entire clinical activity
to 31 May 2016, and includes data already published (to
September 2015).[27]
As of May 2016, 43 patients were considered for
eCLIPs implantation at a bifurcation, the majority at
basilar and carotid termini. The eCLIPs Device was
successfully deployed in 79% of patients considered
for eCLIPs treatment (34/43). The reasons for non-
deployment – the nine abandoned cases – included
a change in or a difference in interpretation of the
anatomy from the screening CTA to digital angiogra-
phy at the time of the procedure, and caution in
application of a new device in challenging anatomic
situations (‘learning curve’ issues). Of the 34 implants,
two of the patients did not meet inclusion criteria
(giant aneurysms) and two with very wide and broad
necks had a strategy of ‘neck narrowing’ rather than
full bridging of the neck with the eCLIPs device.
Therefore, 30 patients met criteria that ordinarily
would be included in a clinical trial of bifurcation
aneurysms, and comparative to most of the published
literature for this anatomic subset. Of these, 18
reached at least a six-month time period after the
index procedure and available for imaging and clin-
ical follow-up. One of these died of an unrelated
traumatic event,1 eight months after the procedure
but before follow-up imaging could be completed,
leaving 17 patients, presented in Figure 4.
From the Index procedure to follow-up, no patient
had a regression in Raymond Score.[28]
Shown more analytically in Figure 5, at the time of
the procedure, 12% (N = 2/17) of patients had achieved
complete aneurysm occlusion (Raymond 1), 41% (N = 7/
17) had partial occlusion (Raymond 2), and 47% (N = 8/
17) had persistent aneurysms (Raymond 3), indicating
loose coiling. At the 6–9-month follow-up, no patient
had a persistent aneurysm (Raymond 3) (N = 0 /17), and
all had either Raymond 1 score (41%) or Raymond 2
score (59%).
Safety
Complications in the entire cohort of 43 patients are
shown in Table 1.[27]
Figure 3. Graphic illustration of disposition of all patients considered for eCLIPs implantation from 2013 to 31 May 2016.
1Traumatic, alcohol-related (Denmark)
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In eCLIPS implanted patients, two (N = 2/34)
adverse events (Table 2) occurred after the eCLIPS
procedure. There was one instance of residual at the
neck region which was recoiled three months later.
There was another instance where a patient had
symptoms of subarachnoid hemorrhage (SAH) one
week after the eCLIPs procedure requiring re-treat-
ment with six nano-coils.[27]
Discussion
This continued improvement of Raymond Score from
procedure to follow-up in patients treated with
eCLIPs as seen in Figure 3 is unique compared to
current methods used to treat bifurcation aneur-
Figure 4. Raymond scores at index procedure and at follow-up
in all patients reaching at least six-month anniversary after
eCLIPs implantation.
Figure 5. Percentage of patients allocated to Raymond scores
1–3 at index procedure and at follow-up.
Table 1. Complications documented in all patients considered
for implantation of eCLIPs device.
Complication
Number of
patients Comment
Death2 3 2 giant3;[27] 1 guide wire
perforation4
Stroke 1 Guide wire perforation5
Transient ischemic
attack
2 Transient cortical blindness;
transient aphasia
Table 2. Procedural adverse events documented in all patients
considered for implantation of eCLIPs device.
Adverse
events
Number of
patients Comment
Dissection 1 Asymptomatic6
Vasospasm 4 Asymptomatic; resolved with catheter
removal and administration of
vasodilating agent7
Thrombotic
event
2 Asymptomatic8
Figure 6. Comparative follow-up data versus Index procedure
(eCLIPs vs. stent assisted coiling, SAC).
2No deaths occurred at the time of eCLIPs procedure
3Late rupture and mass effect; death at 10 and four months, respectively (Canada)
4Hemorrhage over the pericallosal region, with mass effect inferiorly; subsequent review of case images suggested that the
bleeding was likely due to distal wire perforation during first branch access (UK).
5Distal to the target site (i.e. not device related); amongst the group in whom no eCLIPs device was implanted.
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ysms, most notably stent assisted coiling (SAC), as
illustrated in Figure 6.
Typically, SAC is associated with regression in at least
20% of cases from procedure to follow up.[7]
The efficacy results of the preliminary eCLIPs registry of
patients meeting inclusion criteria for management of
wide-neck bifurcation aneurysms, though numbers are
small, show superior results to preliminary results from
clinical trials with similar inclusion criteria for alternative
management options for bifurcation aneurysms, illustrated
in Figure 7. While no eCLIPs patient had a Raymond 3 score
at follow-up, patients treated with a variety of devices
reportedly have 20–37% Raymond 3 at follow-up.
In other words, across the gamut of devices used to
manage this complex anatomic subset, dual stenting,
coil-retaining devices, and intrasaccular devices, persis-
tent or recurrent aneurysms (Raymond Score 3) are
common at follow-up.
The safety profile is analogous to that reported for
similar trials.
Conclusion
The preliminary efficacy results from the on-going
registry support the potential clinical benefit of
eCLIPs in patients with bifurcations aneurysms, par-
ticularly at the basilar and carotid termini. In this
population, these data highlight successful access
to the target vasculature and deployment of eCLIPs
device with an acceptable safety profile. The registry
suggests an unprecedented long-term improvement
to the patient outcome of treating bifurcation intra-
cranial aneurysms with a favorable aneurysmal
occlusion rate and no evidence of recurrence or
persistence at six months follow-up.
These results are favorable enough to justify a formal
prospective clinical trial for verification.
A thoughtful and transparent analysis of preliminary
registry data can identify a patient cohort with similar
characteristics as exists in published reports, as justifica-
tion for developing a formal prospective clinical trial
whose outcome should be integral to furthering clinical
care policies and treatment paradigms, particularly in
rare and complex conditions.
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